microcirculationРегионарное кровообращение и микроциркуляцияRegional blood circulation and microcirculation1682-66552712-9756Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1682-6655-2012-11-4-91-94microcirculation-841Research ArticleКРАТКОЕ СООБЩЕНИЕBRIEF SURVEYРоль асимметричного диметиларгинина в патогенезе сосудистых осложнений сахарного диабетаThe role of asymmetric dimethylarginine in the pathogenesis of vascular disease in diabetes mellitusКравчукЕ. Н.KravchukE. N.noemail@neicon.ruГалагудзаМ. М.GalagudzaM. M.galagoudza@mail.ruКарповА. А.KarpovA. A.noemail@neicon.ruФедоровА. В.FedorovA. V.noemail@neicon.ruРодионовР. Н.RodionovR. N.noemail@neicon.ruФедеральный центр сердца, крови и эндокринологии им. В. А. АлмазоваРоссияV. A. Almazov Federal Center of Heart, Blood and EndocrinologyRussian FederationФедеральный центр сердца, крови и эндокринологии им. В. А. Алмазова; Санкт-Петербургский государственный медицинский университет им. акад. И. П. ПавловаРоссияV. A. Almazov Federal Center of Heart, Blood and Endocrinology; I. P. Pavlov State Medical UniversityRussian FederationТехнологический Университет ДрезденаРоссияTechnical University of DresdenRussian Federation2012301220121149194Copyright © Кравчук Е.Н., Галагудза М.М., Карпов А.А., Федоров А.В., Родионов Р.Н., 20122012Кравчук Е.Н., Галагудза М.М., Карпов А.А., Федоров А.В., Родионов Р.Н.Kravchuk E.N., Galagudza M.M., Karpov A.A., Fedorov A.V., Rodionov R.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.microcirc.ru/jour/article/view/841

Сахарный диабет является одним из наиболее распространенных хронических заболеваний и представляет собой серьезную проблему здравоохранения, в первую очередь, в силу развития осложнений. Развитие эндотелиальной дисфункции является одним из наиболее ранних событий в патогенезе сосудистых осложнений сахарного диабета. Асимметричный диметиларгинин (АДМА), являющийся хорошо известным маркером сердечно-сосудистого риска, может играть роль и при сахарном диабете. Результаты исследований, проведенных в последние годы, остаются противоречивыми. В данном кратком обзоре сделана попытка оценить взаимосвязь уровня АДМА с развитием эндотелиальной дисфункции и сосудистых осложнений при сахарном диабете.

Diabetes mellitus is one of the most common chronic diseases worldwide and represents a challenge for the healthcare system, mainly because of the life-threatening complications. Endothelial dysfunction is an early marker of vascular complications in the patients with diabetes mellitus. Asymmetric dimethylarginine (ADMA) is generally known as a marker of cardiovascular risk which may be also involved in diabetes mellitus. The results of the studies on the role of ADMA in the patients with diabetes mellitus remain controversial. In this review, we summarize recent data on the relationship between ADMA levels and endothelial dysfunction resulting in vascular complications of diabetes mellitus.

асимметричный диметиларгининсахарный диабетэндотелиальная дисфункциясердечнососудистые заболеванияasymmetric dimethylargininediabetes mellitusendothelial dysfunctioncardiovascular diseaseReferencesРодионов, Р. Н. Асимметричный диметиларгинин и его роль в этиологии и патогенезе сердечно-сосудистых заболеваний / Р. Н. Родионов [и др.] // Артериальная гипертензия. - 2008. - Т. 14. - № 4. - С. 306-314.Родионов, Р. Н. Асимметричный диметиларгинин и его роль в этиологии и патогенезе сердечно-сосудистых заболеваний / Р. Н. Родионов [и др.] // Артериальная гипертензия. - 2008. - Т. 14. - № 4. - С. 306-314.Рябов, С. И. Внутренние болезни / С. И. Рябов, В. А. Алмазов, Е. В. Шляхто. - СПб.:Спецлит., 2001. - 861 с.Рябов, С. И. Внутренние болезни / С. И. Рябов, В. А. Алмазов, Е. В. Шляхто. - СПб.:Спецлит., 2001. - 861 с.Abbasi, F. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus / F. Abbasi [et al] // Am. J. Cardiol. - 2001. - Vol. 88. - № 10. - P. 1201-1203.Abbasi, F. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus / F. Abbasi [et al] // Am. J. Cardiol. - 2001. - Vol. 88. - № 10. - P. 1201-1203.Abhary, S. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines / S. Abhary [et al] // Diabetes Care. - 2009. - Vol. 32. - № 11. - P. 2084-2086.Abhary, S. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines / S. Abhary [et al] // Diabetes Care. - 2009. - Vol. 32. - № 11. - P. 2084-2086.Altinova, A. E. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations / A. E. Altinova [et al] // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92. - № 5. - P. 1881-1885.Altinova, A. E. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations / A. E. Altinova [et al] // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92. - № 5. - P. 1881-1885.Anderssohn, M. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: An intriguing interaction with diabetes mellitus / M. Anderssohn [et al.] // Diab. Vasc. Dis. Res. - 2010. - Vol. 7. - № 2. - P. 105-118.Anderssohn, M. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: An intriguing interaction with diabetes mellitus / M. Anderssohn [et al.] // Diab. Vasc. Dis. Res. - 2010. - Vol. 7. - № 2. - P. 105-118.Anthony, S. Endogenous production of nitric oxide synthase inhibitors / S. Anthony [et al.] // Vasc. Med. - 2005. - Vol. 10. - Suppl. 1. - P. S3-S9.Anthony, S. Endogenous production of nitric oxide synthase inhibitors / S. Anthony [et al.] // Vasc. Med. - 2005. - Vol. 10. - Suppl. 1. - P. S3-S9.Boger, R. H. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease / R. H. Boger [et al.] // Circulation. - 1997. - Vol. 95. - № 8. - P. 2068-2074.Boger, R. H. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease / R. H. Boger [et al.] // Circulation. - 1997. - Vol. 95. - № 8. - P. 2068-2074.Boger, R. H. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: its role in hypercholesterolemia / R. H. Boger [et al.] // Circulation. - 1998. - Vol. 98. - № 18. - P 1842-1847.Boger, R. H. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: its role in hypercholesterolemia / R. H. Boger [et al.] // Circulation. - 1998. - Vol. 98. - № 18. - P 1842-1847.Boger, R. H. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia / R. H. Boger [et al.] // Arterioscler. Thromb. Vasc. Biol. - 2000. - Vol. 20. - № 6. - P. 1557-1564.Boger, R. H. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia / R. H. Boger [et al.] // Arterioscler. Thromb. Vasc. Biol. - 2000. - Vol. 20. - № 6. - P. 1557-1564.Boger, R. H. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community / R. H. Boger [et al.] // Circulation. - 2009. - Vol. 119. - № 12. - P. 1592-1600.Boger, R. H. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community / R. H. Boger [et al.] // Circulation. - 2009. - Vol. 119. - № 12. - P. 1592-1600.Cavusoglu, E. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography / E. Cavusoglu [et al.] // Atherosclerosis. - 2010. - Vol. 210. - № 1. - P. 226-231.Cavusoglu, E. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography / E. Cavusoglu [et al.] // Atherosclerosis. - 2010. - Vol. 210. - № 1. - P. 226-231.Cooke, J. P. Asymmetrical dimethylarginine: the Uber marker? / J. P. Cooke // Circulation. - 2004. - Vol. 109. - № 15. - P. 1813-1818.Cooke, J. P. Asymmetrical dimethylarginine: the Uber marker? / J. P. Cooke // Circulation. - 2004. - Vol. 109. - № 15. - P. 1813-1818.Didion, S. P. Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes / S. P. Didion [et al.] // Stroke. - 2005. - Vol. 36. - № 2. - P. 342-347.Didion, S. P. Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes / S. P. Didion [et al.] // Stroke. - 2005. - Vol. 36. - № 2. - P. 342-347.Eid, H. M. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin / H. M. Eid [et al.] // Atherosclerosis. - 2003. - Vol. 166. - № 2. - P. 279-284.Eid, H. M. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin / H. M. Eid [et al.] // Atherosclerosis. - 2003. - Vol. 166. - № 2. - P. 279-284.Ellger, B. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity / B. Ellger [et al.] // Endocrinology. - 2008. - Vol. 149. - № 6. - P. 3148-3157.Ellger, B. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity / B. Ellger [et al.] // Endocrinology. - 2008. - Vol. 149. - № 6. - P. 3148-3157.Gunnett, C. A. Gene-targeted mice reveal a critical role for inducible nitric oxide synthase in vascular dysfunction during diabetes / C. A. Gunnett [et al.] // Stroke. - 2003. - Vol. 34. - № 12. - P. 2970-2974.Gunnett, C. A. Gene-targeted mice reveal a critical role for inducible nitric oxide synthase in vascular dysfunction during diabetes / C. A. Gunnett [et al.] // Stroke. - 2003. - Vol. 34. - № 12. - P. 2970-2974.Hanai, K. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes / K. Hanai [et al.] // Nephrol. Dial. Transplant. - 2009. - Vol. 24. - № 6. - P. 1884-1888.Hanai, K. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes / K. Hanai [et al.] // Nephrol. Dial. Transplant. - 2009. - Vol. 24. - № 6. - P. 1884-1888.Heilman, K. Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes / K. Heilman [et al.] // Scand. J. Clin. Lab. Invest. - 2009. - Vol. 69. - № 1. - P. 85-91.Heilman, K. Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes / K. Heilman [et al.] // Scand. J. Clin. Lab. Invest. - 2009. - Vol. 69. - № 1. - P. 85-91.Howard, B. V. Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology / B. V. Howard [et al.] // Circulation. - 2002. - Vol. 105. - № 18. - P. e132-e137.Howard, B. V. Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology / B. V. Howard [et al.] // Circulation. - 2002. - Vol. 105. - № 18. - P. e132-e137.Jehlicka, P. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1 / P. Jehlicka [et al.] // Physiol. Res. - 2009. - Vol. 58. - № 2. - P. 179-184.Jehlicka, P. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1 / P. Jehlicka [et al.] // Physiol. Res. - 2009. - Vol. 58. - № 2. - P. 179-184.Kanazawa, I. Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus /I. Kanazawa [et al.] // Clin. Endocrinol. - 2011. - Vol. 74. - № 4. - P. 467-472.Kanazawa, I. Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus /I. Kanazawa [et al.] // Clin. Endocrinol. - 2011. - Vol. 74. - № 4. - P. 467-472.Konukoglu, D. The relationship between plasma asymmetrical dimethyl-l-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance / D. Konukoglu [et al.] // Metabolism. - 2008. - Vol. 57. - № 1. - P 110-115.Konukoglu, D. The relationship between plasma asymmetrical dimethyl-l-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance / D. Konukoglu [et al.] // Metabolism. - 2008. - Vol. 57. - № 1. - P 110-115.Lee, I. S. Specific expression of alanine-glyoxylate aminotransferase 2 in the epithelial cells of Henle's loop /1. S. Lee [et al.] // Nephron. - 1999. - Vol. 83. - № 2. - P 184-185.Lee, I. S. Specific expression of alanine-glyoxylate aminotransferase 2 in the epithelial cells of Henle's loop /1. S. Lee [et al.] // Nephron. - 1999. - Vol. 83. - № 2. - P 184-185.Leiper, J. Disruption of methylarginine metabolism impairs vascular homeostasis / J. Leiper [et al.] // Nat. Med. - 2007. - Vol. 13. - № 2. - P. 198-203.Leiper, J. Disruption of methylarginine metabolism impairs vascular homeostasis / J. Leiper [et al.] // Nat. Med. - 2007. - Vol. 13. - № 2. - P. 198-203.Lin, K. Y. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase / K. Y. Lin [et al.] // Circulation. - 2002. - Vol. 106. - № 8. - P. 987-992.Lin, K. Y. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase / K. Y. Lin [et al.] // Circulation. - 2002. - Vol. 106. - № 8. - P. 987-992.Marcovecchio, M. L. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes / M. L. Marcovecchio [et al.] // Clin. Sci. - 2008. - Vol. 115. - № 12. - P. 361-369.Marcovecchio, M. L. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes / M. L. Marcovecchio [et al.] // Clin. Sci. - 2008. - Vol. 115. - № 12. - P. 361-369.Mittermayer, F. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus / F. Mittermayer [et al.] // Wien. Klin. Wochenschr. - 2005. - Vol. 117. - № 23-24. - P. 816-820.Mittermayer, F. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus / F. Mittermayer [et al.] // Wien. Klin. Wochenschr. - 2005. - Vol. 117. - № 23-24. - P. 816-820.Miyazaki, H. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis / H. Miyazaki [et al.] // Circulation. - 1999. - Vol. 99. - № 9. - P 1141-1146.Miyazaki, H. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis / H. Miyazaki [et al.] // Circulation. - 1999. - Vol. 99. - № 9. - P 1141-1146.Nijveldt, R. J. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality / R. J. Nijveldt [et al.] // Clin. Nutr. - 2003. - Vol. 22. - № 1. - P. 23-30.Nijveldt, R. J. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality / R. J. Nijveldt [et al.] // Clin. Nutr. - 2003. - Vol. 22. - № 1. - P. 23-30.Ogawa, T. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney / T. Ogawa [et al.] // J. Biol. Chem. - 1989. - Vol. 264. - № 17. - P. 10205-10209.Ogawa, T. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney / T. Ogawa [et al.] // J. Biol. Chem. - 1989. - Vol. 264. - № 17. - P. 10205-10209.Ogawa, T. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine: glyoxylate aminotransferase 2 / T. Ogawa [et al.] // J. Biol. Chem. -1990. - Vol. 265. - № 34. - P 20938-20945.Ogawa, T. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine: glyoxylate aminotransferase 2 / T. Ogawa [et al.] // J. Biol. Chem. -1990. - Vol. 265. - № 34. - P 20938-20945.Paiva, H. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerularfiltration rate but not with risk factors of vasculopathy / H. Paiva [et al.] //Metabolism. - 2003. - Vol. 52. - № 3. - P. 303-307.Paiva, H. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerularfiltration rate but not with risk factors of vasculopathy / H. Paiva [et al.] //Metabolism. - 2003. - Vol. 52. - № 3. - P. 303-307.Pettersson, A. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia / A. Pettersson [et al.] // Acta Obstet. Gynecol. Scand. - 1998. - Vol. 77. - № 8. - P. 808-813.Pettersson, A. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia / A. Pettersson [et al.] // Acta Obstet. Gynecol. Scand. - 1998. - Vol. 77. - № 8. - P. 808-813.Siroen, M. P. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? / M. P. Siroen [et al.] // Crit. Care Med. - 2005. - Vol. 33. - № 3. - P. 504-510.Siroen, M. P. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? / M. P. Siroen [et al.] // Crit. Care Med. - 2005. - Vol. 33. - № 3. - P. 504-510.Stojanovic, I. The importance of l-arginine metabolism modulation in diabetic patients with distal symmetric polyneuropathy / I. Stojanovic [et al.] // J. Neurol. Sci. - 2012. - DOI: 10.1016/j.jns.2012.09.026.Stojanovic, I. The importance of l-arginine metabolism modulation in diabetic patients with distal symmetric polyneuropathy / I. Stojanovic [et al.] // J. Neurol. Sci. - 2012. - DOI: 10.1016/j.jns.2012.09.026.Sugai, M. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients / M. Sugai [et al.] // Endocr. J. - 2007. - Vol. 54. - № 2. - P. 303-309.Sugai, M. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients / M. Sugai [et al.] // Endocr. J. - 2007. - Vol. 54. - № 2. - P. 303-309.Surdacki, A. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension / A. Surdacki [et al.] // J. Cardiovasc. Pharmacol. - 1999. - Vol. 33. - № 4. - P. 652-658.Surdacki, A. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension / A. Surdacki [et al.] // J. Cardiovasc. Pharmacol. - 1999. - Vol. 33. - № 4. - P. 652-658.Sydow, K. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity / K. Sydow [et al.] // Arterioscler. Thromb. Vasc. Biol. - 2008. - Vol. 28. - № 4. - P. 692-697.Sydow, K. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity / K. Sydow [et al.] // Arterioscler. Thromb. Vasc. Biol. - 2008. - Vol. 28. - № 4. - P. 692-697.Tarnow, L. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes / L. Tarnow [et al.] // Diabetes Care. - 2004. - Vol. 27. - № 3. - P 765-769.Tarnow, L. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes / L. Tarnow [et al.] // Diabetes Care. - 2004. - Vol. 27. - № 3. - P 765-769.Usui, M. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure / M. Usui [et al.] // Life Sci. - 1998. - Vol. 62. - № 26. - P 2425-2430.Usui, M. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure / M. Usui [et al.] // Life Sci. - 1998. - Vol. 62. - № 26. - P 2425-2430.Valkonen, V. P. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine / V. P. Valkonen [et al.] // Lancet. - 2001. - Vol. 358. - P 2127-2128.Valkonen, V. P. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine / V. P. Valkonen [et al.] // Lancet. - 2001. - Vol. 358. - P 2127-2128.Wild, S. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 / S. Wild [et al.] // Diabetes Care. - 2004. - Vol. 27. - P. 1047-1053.Wild, S. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 / S. Wild [et al.] // Diabetes Care. - 2004. - Vol. 27. - P. 1047-1053.Woodman, R. J. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy / R. J. Woodman [et al.] // Drugs. - 2005. - Vol. 65. - P. 31-74.Woodman, R. J. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy / R. J. Woodman [et al.] // Drugs. - 2005. - Vol. 65. - P. 31-74.Xiong, Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes / Y. Xiong [et al.] // Life Sci. - 2005. - Vol. 77. - P. 149-159.Xiong, Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes / Y. Xiong [et al.] // Life Sci. - 2005. - Vol. 77. - P. 149-159.Yoo, J. H. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke / J. H. Yoo, S. C. Lee // Atherosclerosis. - 2001. - Vol. 158. - № 2. - P. 425-430.Yoo, J. H. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke / J. H. Yoo, S. C. Lee // Atherosclerosis. - 2001. - Vol. 158. - № 2. - P. 425-430.Zoccali, C. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study / C. Zoccali [et al.] // Lancet. - 2001. - Vol. 358. - P. 2113-2117.Zoccali, C. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study / C. Zoccali [et al.] // Lancet. - 2001. - Vol. 358. - P. 2113-2117.

The authors declare that there are no conflicts of interest present.